Cytiva

2023年7月13日

닫기生物产业在全球下降在过去的两年里,韩国在亚洲排名第三Cytiva制药和生物技术复苏指数,世界人口生命科学公司说。韩国的弹性生物造成强有力的政府政策和法规,但国家缺乏投资人力资源和研发生态系统,它说。Cytiva韩总裁Choi Jun-ho解释了2023年全球生物制药韧性指数报告的研究结果。(信贷:KBR)注意,Cytiva韩国首席执行官崔Jun-ho解开了制药和生物技术一起复苏指数从近期2023年全球生物制药行业的见解韧性指数报告在Coex周四举行的新闻发布会上,首尔,2023年Bioplus-Interphex间隙。“在快速增长的韩国制药和生物技术市场,培养人才和提高研发的最紧迫的挑战是生态环境,政府,行业和学术界必须解决在一起,”崔说。“我们致力于促进国内生物人才和加强研发通过我们亚太区的Songdo快速通道中心,仁川,和其他各种industry-academia合作项目。“Cytiva教育中心,成立于2016年,提供了生物工艺的专业知识。崔也指出其他人力资源培训项目与韩国国立生物工艺研究和培训(K-NIBRT)预计明年推出。Cytiva韧性指数是基于1250年制药公司和生物技术高管的调查和医疗政策制定者从22个国家,包括韩国,以及与行业专家深度访谈。调查参与者评估他们的国家的地位基于规模的1到10基于五根柱子的弹性供应链、人力资源、研发生态系统,制造敏捷性,和政府的政策和法规。图表显示了2023年全球制药和生物技术复苏指数的国家排名,绿色代表亚洲国家和灰色代表其他国家。 (Credit: Cytiva) This year, the global recovery index was 6.08 out of 10, an overall decline from 2021 (6.6). Supply chain resilience and manufacturing agility, which have seen significant investment during the pandemic, rose slightly, but human resources, R&D ecosystems, and government policies and regulations fell, indicating that they remain a challenge. By country, Switzerland (6.98), the United States (6.96), and the United Kingdom (6.78) showed the most promise for the pharma and biotech industry but Thailand (5.36), Saudi Arabia (5.20), and the United Arab Emirates (5.17), which rely heavily on imports, ranked lower. In Asia, Singapore (6.41) ranked highest, followed by Japan (6.06) and South Korea (6.05). Specifically, South Korea, which ranked seventh in the world and first in Asia in 2021, dropped to 12th in the world and third in Asia this year. The rankings reflected Korea’s strong government support and regulatory reform, maintaining its top spot at number four but the other factors such as human resources dropped to 16th and R&D ecosystems dropped to 12th, seeing relatively large declines from two years ago. The decline in ranking suggests the need to attract talent, create public and private education infrastructure, find R&D partners, and make open innovation a reality reasoned Cytiva’s CEO. Additionally, supply chain resilience and manufacturing agility also received low scores, ranking at 14 and 15 respectively. The report further noted that there were also positive trends around mid-ranking countries in the index, in particular South Korea, where the government has promised an annual investment of $303 million to nurture the national biotech industry. This investment is accompanied by several regulatory reforms intended to streamline innovation, decentralize clinical trials, and de-risk investment in new therapies, it went on to state.